摘要
目的评价卡维地洛配伍开博通在慢性心力衰竭（CHF）患者中应用的安全性及疗效观察。方法26例CHF患者（男15例，女11例）平均年龄57岁，心动能Ⅱ-Ⅳ级，左室射血分数（LVEF）34％。卡维地洛剂量从3．125mg，2次／d起，只要能耐受，尽可能递增到25～50mg·d。维持，开博通每天，12．5～50mg。共观察6个月，治疗中观察各项相关指标。结果治疗后心功能和6min步行距离较治疗前明显改善，（2．18±0．72）比（3．12±0．69）和（208±164）m比（322±168）m，P〈0．05，心超枰查左室舒张末经（LVEDD）和左室收缩末经（LVESD）明显减少，（63．48±9．7）mm比（57．90±9．01）mm和（51．10±10．90）mm比（46．98±10．48）mm，P〈0．05，LVEF明显增加（28．61±8．8）％比（43．76±10．98）％，P〈0．01，少数人出现咳嗽，血K＋升高，乏力等。结论卡维地洛配伍开通治疗慢性心力衰竭是安全的，能明显改善活动耐量，改善心动能，增加LVEF。
Aim To evaluate the safety and clinical efficacy of earvedilol and captopril in patients with chronic congestive heart failure （CHF）. Methods Twenty-six patients with CHF（ male 15 ,female 11 ） , average age of 57 years old and average EF 34%, underwent carvedilol therapy with a dosage of 3.125mg to 25 -50 mg perday if they were tolerated for six months, combined with eaptopril at a dose of 12.5 - 100 mg once daily for six months. Results After the treatment, NYHA classification and 6 minte walk distance were improved （ 2.18 ±0.72）vs （3.12 ±0.69） ; （208 ± 164） m vs （322 ± 168） m,P 〈0.05 respectively. LVEDD and LVESD measured by echoeardiography reduced （63.48 ±9.7 ）mm vs （ 57.90 ± 9. 01 ） mm ; （ 51.10 ± 10.90 ） mm vs （ 46.98 ± 10.48 ） mm P 〈 0.01, respectively. Left ventrieular eject fraction （LVEF） increased （28.61 ± 8.8 ） % vs （43.76 ±10.98 ） % , P 〈 0. 01. Cough and serum potassium increased （P 〈 0.05 ）. Conclusion The application of carvedilol and captopril to the treatment of ehronie heart failure is safe and effective.
出处
《安徽医药》
CAS
2009年第5期551-553,共3页
Anhui Medical and Pharmaceutical Journal
